Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.

Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA.

Circulation. 2010 Oct 12;122(15):1478-87. doi: 10.1161/CIRCULATIONAHA.110.947960. Epub 2010 Sep 27.

PMID:
20876434
[PubMed - indexed for MEDLINE]
Free Article
2.
3.

High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention.

Ridker PM.

Am J Cardiol. 2003 Aug 21;92(4B):17K-22K. Review.

PMID:
12948872
[PubMed - indexed for MEDLINE]
4.

[Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events].

Schwarzer R, Schnell-Inderst P, Grabein K, Göhler A, Stollenwerk B, Grandi N, Klauss V, Wasem J, Siebert U.

Z Evid Fortbild Qual Gesundhwes. 2009;103(6):319-29. Review. German.

PMID:
19839204
[PubMed - indexed for MEDLINE]
5.

High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease.

Yeh ET.

Clin Cardiol. 2005 Sep;28(9):408-12. Review.

PMID:
16250263
[PubMed - indexed for MEDLINE]
6.

C-reactive protein: a new risk assessment tool for cardiovascular disease.

Clearfield MB.

J Am Osteopath Assoc. 2005 Sep;105(9):409-16. Review.

PMID:
16239491
[PubMed - indexed for MEDLINE]
Free Article
7.

The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.

Kones R.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):309-15. doi: 10.1177/1753944709337056. Epub 2009 May 21. Review.

PMID:
19460829
[PubMed - indexed for MEDLINE]
8.

[From lipid target values to the JUPITER study. Significance of achieving lipid levels specified by the guidelines and deficiencies in practice].

Márk L, Katona A.

Orv Hetil. 2009 Nov 1;150(44):2012-8. doi: 10.1556/OH.2009.28740. Review. Hungarian.

PMID:
19861287
[PubMed - indexed for MEDLINE]
9.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
[PubMed - indexed for MEDLINE]
10.

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.

Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA.

Health Technol Assess. 2000;4(29):1-123. Review.

PMID:
11109029
[PubMed - indexed for MEDLINE]
Free Article
11.

Impact of C-reactive protein on treatment of patients with cardiovascular disease.

Gortney JS, Sanders RM.

Am J Health Syst Pharm. 2007 Oct 1;64(19):2009-16. Review.

PMID:
17893410
[PubMed - indexed for MEDLINE]
12.

Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.

Koenig W.

Int J Cardiol. 2005 Feb 15;98(2):199-206. Review.

PMID:
15686768
[PubMed - indexed for MEDLINE]
13.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
[PubMed - indexed for MEDLINE]
14.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
[PubMed - indexed for MEDLINE]
15.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

PMID:
15297292
[PubMed - indexed for MEDLINE]
Free Article
16.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

PMID:
15249516
[PubMed - indexed for MEDLINE]
Free Article
17.

Moving toward new statin guidelines in a post-JUPITER world: principles to consider.

Ridker PM.

Curr Atheroscler Rep. 2009 Jul;11(4):249-56. Review.

PMID:
19500487
[PubMed - indexed for MEDLINE]
18.

C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.

Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL.

Postgrad Med. 2011 Jan;123(1):114-9. doi: 10.3810/pgm.2011.01.2252. Review.

PMID:
21293091
[PubMed - indexed for MEDLINE]
19.

Connecting the role of C-reactive protein and statins in cardiovascular disease.

Ridker PM.

Clin Cardiol. 2003 Apr;26(4 Suppl 3):III39-44. Review.

PMID:
12708638
[PubMed - indexed for MEDLINE]
20.

Statin therapy in the elderly: does it make good clinical and economic sense?

Mungall MM, Gaw A, Shepherd J.

Drugs Aging. 2003;20(4):263-75. Review.

PMID:
12641482
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk